Last reviewed · How we verify

Sydney Centre for Reproductive Health Research — Portfolio Competitive Intelligence Brief

Sydney Centre for Reproductive Health Research pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
E2Nomac E2Nomac marketed Selective Estrogen Receptor Modulator (SERM) Estrogen receptor (ER-α/ER-β) Reproductive Health / Gynecology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 1 shared drug class
  2. Sebela Women's Health Inc. · 1 shared drug class
  3. Wyeth is now a wholly owned subsidiary of Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sydney Centre for Reproductive Health Research:

Cite this brief

Drug Landscape (2026). Sydney Centre for Reproductive Health Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sydney-centre-for-reproductive-health-research. Accessed 2026-05-18.

Related